Abbott receives fda approval for hpv test to run on alinity m, offering primary hpv screening and assessment of high-risk cancer-causing types of hpv

According to the u.s. centers for disease control (cdc), most sexually active adults will experience hpv infections; new test detects those hpv genotypes that could lead to cancer abbott's new hpv test uses molecular technology to provide genotype determination on the 14 high-risk, cancer-causing types of hpv the test is one of the fewi hpv tests approved for use as a primary screen for cervical cancer as recommended by professional guidelines   abbott park, ill., nov. 2, 2023 /prnewswire/ -- abbott (nyse: abt) has received u.s. food and drug administration (fda) approval for its molecular human papillomavirus or hpv screening solution, adding a powerful cancer screening tool for detecting high-risk hpv infections to the alinity m family of diagnostic assays.
ABT Ratings Summary
ABT Quant Ranking